Financial Comparison: Ernexa Therapeutics (NASDAQ:ERNA) vs. Profound Medical (NASDAQ:PROF)

Profound Medical (NASDAQ:PROF) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Volatility and Risk

Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500.

Valuation & Earnings

This table compares Profound Medical and Ernexa Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10 million	16.39	-$42.57 million	($1.24)	-5.85
Ernexa Therapeutics	$580,000.00	7.93	-$14.08 million	($26.20)	-0.15

Ernexa Therapeutics has lower revenue, but higher earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Profound Medical and Ernexa Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1	0	1	0	2.00
Ernexa Therapeutics	1	1	1	0	2.00

Profound Medical currently has a consensus price target of $12.00, suggesting a potential upside of 65.29%. Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 663.36%. Given Ernexa Therapeutics’ higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Profound Medical.

Insider & Institutional Ownership

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and Ernexa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.